OpportunityTitle: Limited Competition: Continuation of the Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Non-domestic (non-U.S.) Entities (Foreign Organizations); This FOA is a limited competition for continuation of the TODAY study, which was previously reviewed in response to RFA-DK-08-502. Only the currently funded DCC is eligible to apply. Only the currently funded CCs are eligible to be CCs as subcontracts to the DCC.
Description: The purpose of this Funding Opportunity Announcement (FOA) is to continue follow-up of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort through a cooperative agreement. TODAY was a multi-center controlled clinical trial examining the efficacy of three approaches to treat recently diagnosed type 2 diabetes in youth ages 10-17 years. TODAY demonstrated that combination therapy with metformin plus rosiglitazone sustained glycemic control longer than either metformin plus an intensive lifestyle program or metformin alone.TODAY study results also suggest that type 2 diabetes is more aggressive when it occurs at a young age. The primary purpose of this FOA is to continue follow-up of the TODAY cohort to define the long-term clinical course of youth-onset type 2 diabetes.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;